About Adcock Ingram Limited
Data last updated:
Adcock Ingram Limited is a public limited company based in Bangalore, Karnataka, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 03 April 2007 and has been in existence for over 19 years.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U24232KA2007PLC042361. Its GSTIN is 29AAGCA4343M1ZD (Karnataka).
The company has an authorised share capital of ₹40 Cr and a paid-up capital of ₹38.05 Cr. It is led by directors including Ammanna Chowdary Yarlagadda (Managing Director) and Pravin Vaidyanathan Iyer.
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Plot No. 49 D Bommasandra Industrial Area Annekal Taluk, Bangalore, Karnataka, India – 560099.
As per the financials filed for FY 2025, the company reported a revenue of ₹463.95 Cr, a growth of 8% compared to the previous year. For the same year it recorded a net profit of ₹99.21 Cr (net margin 21.4%) and EBITDA of ₹150.83 Cr (EBITDA margin 32.5%).
The company has about 452 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary and 1 joint venture.
As per MCA filings, the company has open charges of ₹27.5 Cr and satisfied charges of ₹84.45 Cr on record. Court records list 13 cases involving the company, including 7 filed by the company and 5 filed against it; 4 cases are pending. The company has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹38 Cr; the latest was in February 2008. Its 10 peer companies in the Pharma industry (Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is Cronus Pharma Specialities India Private Limited with revenue of ₹484.74 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website medreich.com.
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered AddressPlot No. 49 D Bommasandra Industrial Area Annekal Taluk, Bangalore, Karnataka, India – 560099
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Adcock Ingram Limited
The main business activity of Adcock Ingram is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Adcock Ingram Limited FY 2025 filings available
Adcock Ingram Limited reported revenue of ₹463.95 Cr (up 8% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Adcock Ingram Limited
Revenue rose 8% in the latest year. EBITDA rose 22% in the latest year. All are worked out from the filed statements.
Financial Statement Summary of Adcock Ingram Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹150.83 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹99.21 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Adcock Ingram Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 32.5% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 21.4% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Adcock Ingram are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Adcock Ingram Limited
Adcock Ingram Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Cronus Pharma Specialities India Private Limited | ₹484.74 Cr (FY 2025) | •••• | •••• | 64.0% | •••• | Hyderabad, Telangana, India |
| Syncom Formulations (India) Limited Listed | ₹482.45 Cr (FY 2025) | •••• | •••• | 74.0% | •••• | Mumbai, Maharashtra, India |
| Karnataka Antibiotics and Pharmaceuticals Limited | ₹479.24 Cr (FY 2022) | •••• | •••• | 11.0% | •••• | Bangalore, Karnataka, India |
| Cachet Pharmaceuticals Private Limited | ₹478.02 Cr (FY 2025) | •••• | •••• | 6.0% | •••• | Patna, Bihar, India |
| Jodas Expoim Private Limited | ₹473.22 Cr (FY 2021) | •••• | •••• | 96.0% | •••• | Mulugu, Telangana, India |
| Adcock Ingram Limited this company | ₹463.95 Cr (FY 2025) | •••• | •••• | 8.0% | •••• | Bangalore, Karnataka, India |
| Zee Laboratories Limited | ₹463.57 Cr (FY 2024) | •••• | •••• | 10.0% | •••• | Delhi, India |
| Aristo Laboratories Private Limited | ₹461.43 Cr (FY 2025) | •••• | •••• | 10.0% | •••• | Mumbai, Maharashtra, India |
| Tevapharm India Private Limited | ₹459.24 Cr (FY 2025) | •••• | •••• | -9.0% | •••• | Mumbai, Maharashtra, India |
| Fredun Pharmaceuticals Ltd Listed | ₹456.27 Cr (FY 2025) | •••• | •••• | 31.0% | •••• | Mumbai, Maharashtra, India |
| Hab Pharmaceuticals and Research Limited | ₹448.72 Cr (FY 2025) | •••• | •••• | 19.0% | •••• | Mumbai, Maharashtra, India |
Peers are the five companies nearest above and the five nearest below Adcock Ingram by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Adcock Ingram Limited
Adcock Ingram Limited is audited by S.R. Batliboi & Associates LLP for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| S.R. Batliboi & Associates LLP | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Adcock Ingram Limited
Adcock Ingram has 9 current directors and 21 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Pravin Vaidyanathan Iyer | Director | 10 Jun 2015 | 11 Years 4 Months | Current |
| Pankaj Garg | Director | 15 Sep 2016 | 10 Years 0 Months | Current |
| Yasuhiro Nakagiri Also directs: Adcock Ingram Pharma Private Limited, Medreich Limited | Director | 08 May 2024 | 2 Years 5 Months | Current |
| Shanthakumarie Pather | Director | 28 Sep 2022 | 4 Years 0 Months | Current |
| Ammanna Chowdary Yarlagadda Also directs: Adcock Ingram Pharma Private Limited | Managing Director | 21 Sep 2022 | 4 Years 0 Months | Current |
| Yudhveer Singh Also directs: Adcock Ingram Pharma Private Limited | Director | 24 Jan 2022 | 4 Years 8 Months | Current |
Ownership and Shareholding of Adcock Ingram Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Adcock Ingram Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Mar 2013 | Others | ₹27.5 Cr | Open |
| 28 Dec 2007 | State Bank of Hyderabad | ₹84.45 Cr | Satisfied |
Total charge records: 2 View all charges
Deals & Funding of Adcock Ingram Limited
Adcock Ingram Limited has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹38 Cr; the latest was in February 2008.
Deals on record (2 of 2)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Feb 2008 | Secondary share transfer | Undisclosed | Buyer: Medreich Limited Seller: an individual |
| Nov 2007 | Funding round | ₹38 Cr | Investors: Adcock Ingram Holdings Private Limited, Medreich Limited |
Full deal history
All 2 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Adcock Ingram Limited
Adcock Ingram Limited has 13 court cases on record: 7 filed by Adcock Ingram, 5 filed against it, 1 where it is another party. 4 cases are pending and 9 are disposed. Status as checked between 21 Sep 2026 and 02 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 11 | 4 | 4 |
| District courts | 2 | 1 | 0 |
Cases on record (5 of 13)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Karnataka | Writ petition | Company is another party | Pending |
| High Court of Karnataka | Tax appeal | Filed against the company by PR Commissioner of Income Tax, Cit(A) | Pending |
| High Court of Karnataka | Tax appeal | Filed against the company by PR Commissioner of Income Tax, Cit (A) | Pending |
| High Court of Karnataka | Appeal | Filed against the company by an individual | Pending |
| High Court of Karnataka | Writ petition | Filed by the company against Karnataka State Pollution Control Board | Disposed |
Full case history
All 13 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Employees and EPFO Compliance at Adcock Ingram Limited
Adcock Ingram Limited has a workforce of 452 employees as of Mar 28, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Group Structure of Adcock Ingram Limited
Adcock Ingram has 1 subsidiary company and 1 joint venture. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares Held |
|---|---|---|
| Adcock Ingram Pharma Private Limited | U24299KA2021PTC148184 | Locked |
Showing major subsidiaries. Total: 1.
Recent Activity on Adcock Ingram Limited
Adcock Ingram Limited has 24 board changes on record since 2008: 9 appointments and 15 cessations. The latest: Dorette Neethling was appointed as Director on 19 Feb 2025.
20 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Adcock Ingram Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Adcock Ingram Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Adcock Ingram Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Adcock Ingram Limited
Adcock Ingram has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AAGCA4343M1ZD | Karnataka | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Adcock Ingram Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adcock Ingram Limited
Adcock Ingram is an active public limited company based in Bangalore, Karnataka, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 03 April 2007 (19+ years old) and is registered under CIN U24232KA2007PLC042361.
Adcock Ingram reported revenue of ₹463.95 Cr for FY 2025 (up 8% YoY).
Adcock Ingram has 9 current directors:
- Ammanna Chowdary Yarlagadda - Managing Director
- Pravin Vaidyanathan Iyer - Director
- Pankaj Garg - Director
- Yasuhiro Nakagiri - Director
- Shanthakumarie Pather - Director
- Yudhveer Singh - Director
- Kenshi Murase - Director
- Kensuke Hata - Director
- Dorette Neethling - Director
Adcock Ingram reported a net profit of ₹99.21 Cr (net margin 21.4%) and EBITDA of ₹150.83 Cr (EBITDA margin 32.5%) for FY 2025, as per its filed financial statements.
The GSTIN of Adcock Ingram is 29AAGCA4343M1ZD, registered in Karnataka.
The CIN (Corporate Identification Number) of Adcock Ingram is U24232KA2007PLC042361. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Adcock Ingram has 13 court cases on record: 7 filed by the company and 5 filed against it. 4 are pending. Most are in the high courts.
Adcock Ingram was incorporated on 03 April 2007, making it 19+ years old. It is registered with the Registrar of Companies, Bangalore.
Adcock Ingram has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹38 Cr; the latest was in February 2008.
The peers of Adcock Ingram by revenue are Cronus Pharma Specialities India Private Limited, Syncom Formulations (India) Limited, Karnataka Antibiotics and Pharmaceuticals Limited, Cachet Pharmaceuticals Private Limited, Jodas Expoim Private Limited and 5 more, all in the Pharma industry (Formulations).
Dorette Neethling was appointed as Director on 19 Feb 2025. Yasuhiro Nakagiri was appointed as Director on 08 May 2024. Shanthakumarie Pather was appointed as Director on 28 Sep 2022. Adcock Ingram has 24 board changes on record in total.